GERMAN TARCEVA NON-INTERVENTIONAL STUDY in 1st Line Treatment of NSCLC EGFR Mutation Positive Patients
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Non-Small Cell Lung Cancer
Both
Non-Small Cell Lung Cancer
Trial Information
GERMAN TARCEVA NON-INTERVENTIONAL STUDY in 1st Line Treatment of NSCLC EGFR Mutation Positive Patients
Inclusion Criteria:
- Adult patients, >/= 18 years of age
- Locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer
- Patients for whom the treating physician has decided to initiate first-line therapy
with Tarceva in accordance with the Summary of Product Characteristics and local
guidelines
Exclusion Criteria:
- N/A
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Progression-free survival rate at 18 months
Outcome Time Frame:
3.5 years
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
Hoffmann-La Roche
Authority:
Germany: Federal Institute for Drugs and Medical Devices
Study ID:
ML27895
NCT ID:
NCT01790217
Start Date:
July 2012
Completion Date:
January 2016
Related Keywords:
- Non-Small Cell Lung Cancer
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
Name | Location |
|---|
